Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells

Blood

Volumn 123, Issue 8, 2014, Pages 1218-1228

  Nievergall, Eva ^a,b,c,d,e   Ramshaw, Hayley S ^b,d,f   Yong, Agnes S M ^b,c   Biondo, Mark ^g   Busfield, Samantha J ^g   Vairo, Gino ^g   Lopez, Angel F ^b,d,f   Hughes, Timothy P ^a,b,c,d,e   White, Deborah L ^a,b,c,d,e   Hiwase, Devendra K ^b,c,d  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c SA PATHOLOGY   (Australia)

^d University of Adelaide   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f South Australian Pathology   (Australia)

^g CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; DASATINIB; IMATINIB; INTERLEUKIN 3; MONOCLONAL ANTIBODY; NILOTINIB; STAT5 PROTEIN; IL3RA PROTEIN, HUMAN; INTERLEUKIN 3 RECEPTOR; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER STEM CELL; CELL RENEWAL; CELL VIABILITY ASSAY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; CELL LINE; ERYTHROLEUKEMIA; IMMUNOLOGY; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; STEM CELL;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD34; ANTIGENS, CD38; CELL LINE; FEMALE; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; RECEPTORS, INTERLEUKIN-3; STEM CELLS;

EID: 84899137486     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-475194     Document Type: Article

References (49)

1. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451-1464. (Pubitemid 37211061)
2. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-1630.
3. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009;114(22). Abstract 1126.
4. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-2203.
5. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123-1129.
6. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
7. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
8. Chomel J-C, Bonnet M-L, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657-3660.
9. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565-5572.
10. Mahon F-X, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
11. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
12. Hiwase DK, White DL, Powell JA, et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia. 2010;24(4):771-778.
13. Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007;109(5):2147-2155. (Pubitemid 46348217)
14. Traer E, MacKenzie R, Snead J, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. 2012;26(5):1140-1143.
15. Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 2001;97(3):720-728. (Pubitemid 32113406)
16. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 1999;96(22):12804-12809. (Pubitemid 29513583)
17. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21(5):926-935. (Pubitemid 46672068)
18. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
19. Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18(2):219-226. (Pubitemid 38240035)
20. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood. 1997;89(5):1471-1482. (Pubitemid 27097437)
21. Miyajima A, Mui AL, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood. 1993;82(7):1960-1974. (Pubitemid 23293974)
22. Sun Q, Woodcock JM, Rapoport A, et al. Monoclonal antibody 7G3 recognizes the Nterminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. Blood. 1996;87(1):83-92. (Pubitemid 26018391)
23. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31-42.
24. Busfield SJ, Biondo M, Wong M, et al. CSL362: a monoclonal antibody to human interleukin-3 receptor (CD123), optimized for NK cell-mediated cytotoxicity of AML stem cells [abstract]. Blood. 2012;120(21). Abstract 3598.
25. Matsuo Y, Adachi T, Tsubota T, Imanishi J, Minowada J. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. Hum Cell. 1991;4(3):261-264.
26. Nolta JA, Thiemann FT, Arakawa-Hoyt J, et al. The AFT024 stromal cell line supports long-term ex vivo maintenance of engrafting multipotent human hematopoietic progenitors. Leukemia. 2002;16(3):352-361. (Pubitemid 34223694)
27. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 2002;99(11):4100-4108. (Pubitemid 35332053)
28. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. (Pubitemid 43990609)
29. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 1997;8(1):63-79. (Pubitemid 27214689)
30. Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23):9624-9633.
31. Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34+/CD38 - stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47(2):207-222. (Pubitemid 43084559)
32. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(8):2794-2799.
33. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667. (Pubitemid 39063268)
34. Lee EM, Dean Yee P, Busfield SJ, Vairo G, Lock RB. A neutralizing antibody (CSL362) against the interleukin-3 receptor α-chain augments the efficacy of a cytarabine/daunorubicin induction-type therapy in preclinical xenograft models of acute myelogenous leukemia [abstract]. Blood. 2012;120(21). Abstract 3599.
35. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA. 2009;106(10):3925-3929.
36. Schemionek M, Elling C, Steidl U, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 2010;115(16):3185- 3195.
37. Chen CI, Koschmieder S, Kerstiens L, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2012;26(3):465-474.
38. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 2008;111(8):4415-4416.
39. Fraser CK, Blake SJ, Diener KR, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 2009;37(2):256-265.
40. Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012;53(6):1084-1089.
41. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116(5):772-782.
42. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398-1405.
43. Herzog E, Busfield S, Biondo M, et al. Pharmacodynamic activity and preclinical safety of CSL362, a novel humanised, affinity matured monoclonal antibody against human interleukin 3 receptor [abstract]. Blood. 2012;120(21). Abstract 1524.
44. Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res. 2010;34(8):1035- 1042.
45. Muñoz L, Nomdedéu JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86(12):1261-1269. (Pubitemid 34016712)
46. Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543-553. (Pubitemid 351298340)
47. Konopleva M, Hogge DE, Rizzieri DA, et al. SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML [abstract]. Blood. 2012;120(21). Abstract 3625.
48. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008-2016.
49. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376(9747):1164-1174.